$1.65 billion up front. Another $700 million if the drug works. Telix Pharmaceuticals is buying ITM Isotope Technologies Munich, and the headline price is the least interesting number in the filing.
ITM-11, the therapy carrying most of that $700 million in contingent payments, was rejected by U.S. regulators in August over manufacturing issues at a third-party facility. Telix is buying the factory, the isotope, and a distribution network that reaches more than 65 countries, and treating the drug as a call option. Our read: that is the correct shape for radiopharma in 2026. The scarce asset is supply, and the molecule is the upside.
What the money actually buys
ITM is a 22-year-old Munich company that most readers have never seen on a conference badge. It supplies raw radioisotopes to other drugmakers and runs more than 10 radiopharmaceutical programs of its own. Its supply business booked $273 million in sales in 2025, according to BioPharma Dive.
Telix for ITM, including milestones
$1.65 billion upfront, plus as much as $700 million tied to ITM-11 approvals and sales. · BioPharma Dive, 2026
ITM supply revenue, 2025
The industrial business that anchors the deal, separate from the therapy pipeline. · BioPharma Dive, 2026
Telix shareholders will own about 76.3% of the combined company. Investors holding more than 90% of ITM's shares have already approved the transaction, and closing is expected by the end of Telix's 2026 fiscal year. A shareholder vote is flagged for 1 December 2026.
The market did not celebrate. Reuters reported that about $1.25 billion of the consideration is paid in Telix shares, and that the stock fell almost 6% around the announcement. Dilution plus a manufacturing setback is a hard combination to sell in one morning.
Sixty-five countries, and a clock that never stops
Radiopharmaceuticals are not pills. A dose is manufactured, labelled, shipped, and infused while the isotope is still radioactive. Every handoff burns time that the physics does not give back. ITM describes itself as the world's largest supplier of lutetium-177, the isotope used in Novartis' Pluvicto and Lutathera, and says it has supplied Novartis since 2018. It is also building capacity in actinium-225 through its Actineer joint venture and has terbium-161 on the roadmap.
That industrial footprint is why William Blair's Andy Hsieh wrote that the deal gives Telix "even greater control over the entire radiopharmaceutical value chain" and could let it "corner the industry." Analysts reach for verbs like that when the scarce input is physical, not intellectual.
Pluvicto generated about $2 billion for Novartis in 2025. Lutathera arrived in 2018, Pluvicto in 2022, and the pair turned a decades-old research field into a commercial category. Every company that wants a slice now needs three things at once: a targeting molecule, a manufacturing line, and a logistics network that can move short-lived material to a hospital on the right day.
The constraint is not a shortage of chemists. It is geography. A dose produced in one country and infused in another passes through customs, a radiopharmacy, and a nuclear medicine department that has to book the chair before the activity decays below specification. Every extra border narrows the set of hospitals a supplier can serve. That is why a distribution footprint is an asset with a moat around it, and why buying one is faster than building one.
The layer map
Most coverage of radiopharma M&A collapses four different businesses into one word. They have different economics and different failure modes.
| Layer | What it is | After the deal | Why it is hard to copy |
|---|---|---|---|
| Isotope production | Reactor or accelerator output of Lu-177, Ac-225, Tb-161 | ITM sites and Actineer JV | Permits, precursor supply, years of build time |
| Drug manufacturing | Radiolabelling and fill-finish under GMP | ITM plus Telix facilities | Regulated process, inspection history |
| Distribution | Radiopharmacies and time-critical delivery | Telix and ITM networks across 65+ countries | Cold-chain logistics and local licensing |
| Therapy molecule | ITM-11 and the rest of the pipeline | Telix pipeline | Clinical data, FDA review |
Layer map assembled from BioPharma Dive and ITM disclosures, 2026
Telix already sells diagnostic products and owns pieces of the middle two layers. ITM hands it the top layer at scale. The therapy, the layer most readers focus on, is the one with an open regulatory question.
Why the factory is the regulatory unit
In small-molecule pharma, a chemistry, manufacturing and controls problem is an inconvenience. In radiopharma it is the product. The isotope decays whether or not the paperwork is ready, so every quality deviation lands on a clock that cannot be paused.
That is why the ITM-11 rejection deserves a closer look than the headline "FDA rejects" suggests. The agency cited manufacturing concerns and issues at a third-party commercial facility. The clinical package was not the stated problem. A third-party facility also means a supplier outside the buyer's direct control, which is exactly the kind of dependency that a vertically integrated deal is meant to remove.
Read the merger in that light and the sequencing makes sense. Telix already runs manufacturing and a radiopharmacy network. ITM brings isotope production at scale and a distribution footprint spanning more than 65 countries. The drug is the last piece to be fixed, and it is the piece with a defined remediation path.
There is a second regulatory layer that rarely makes the press release. Radioactive material crosses borders under transport rules that differ by jurisdiction, and each market wants its own site inspection before doses can be sold. Buying an operator with existing licences shortens that queue by years. Building the same footprint from scratch would require permits, irradiation capacity, trained staff, and a inspection record that regulators can read.
This is the part of the deal that does not show up in a pipeline chart. It is also the part that competitors cannot copy with a licensing cheque.
The rejection is the interesting part
ITM-11 pairs lutetium-177 with a compound aimed at the SSTR protein, the same target as Lutathera, in gastroenteropancreatic neuroendocrine tumors. The FDA rejected it in August. ITM said the decision turned on manufacturing concerns and issues at a third-party commercial facility, not on clinical data. Telix called the asset differentiating and pointed to a Phase 3 readout in a second indication expected in 2027.
The refiling path is also a closing condition. That detail matters more than the milestone schedule. A buyer can walk if remediation stalls, and the $700 million contingent stack stays theoretical until the FDA accepts the manufacturing story.
This is where the editorial case for the deal sits. Paying a premium for a rejected drug looks brave. Paying a premium for the largest lutetium supplier, with a rejected drug attached as optionality, looks like capital allocation. The same transaction supports both readings, and only one of them depends on clinical luck.
What would make this deal look expensive
Two clocks, one balance sheet
The merged company runs on two clocks. One is commercial and quarterly: isotope contracts, diagnostic kit sales, and the base business that pays for everything else. The other is clinical and measured in approval cycles, which is where the $700 million lives.
The commercial clock is the stronger of the two right now. ITM's supply business generated $273 million in sales in 2025, and BioPharma Dive reported that the combined company is expected to bank more than $1.3 billion in revenue this year. Telix's third quarter added $245 million of group revenue, up 19% year over year. Those are the numbers that service the purchase price while the therapy clock ticks.
The clinical clock is slower and less predictable. ITM-11 needs a refiling the FDA accepts, then a review, then a launch into a neuroendocrine tumor market where Lutathera already sits. A second Phase 3 indication could read out in 2027. The milestone structure pays only when those events land, which shifts part of the risk back to ITM's sellers.
That structure is the quiet tell. Telix did not pay $2.35 billion in cash on day one. It paid $1.65 billion up front and rented the rest of the story. For a company adding a rejected drug to a working industrial business, that is a disciplined way to buy optionality without pretending the science is settled.
What to watch before the vote
Three dates matter. The shareholder vote is flagged for 1 December 2026. Closing is expected before the end of the fiscal year. The ITM-11 resubmission has no public date, which is the point.
Telix's own numbers give the deal a stable base. Group revenue was $245 million in the third quarter of 2026, up 19% from $206 million a year earlier and down about 1% from the second quarter. Growth is real, and the sequential flattening is the kind of detail that gets buried under a merger announcement.
Watch the vote margin as much as the vote. A narrow win would signal that a meaningful slice of Telix holders share the market's initial skepticism, and that the integration story has to be sold twice. A comfortable win gives management room to absorb the remediation costs without a fresh fight.
Watch the third-party facility, too. If the same site appears in the refiling, the inspection history becomes the single point of failure for the most expensive part of the deal. If Telix moves the process in-house, it buys control at the cost of time.
There are smaller moving parts, too. Telix announced an astatine-211 collaboration with Ekalia in October, a Zircaix resubmission is in progress, and a European review of Pixlumi continues. None of these decide the merger. Together they show a company spreading bets across alpha emitters, imaging agents, and therapeutic isotopes at the same time.
The 1 December shareholder vote and any proxy resistance
FDA acceptance of the ITM-11 refiling, with a date attached
Lutetium-177 contract renewals beyond the current decade
Whether Telix keeps supplying third-party drugmakers after closing
The strategic logic is blunt. Whoever controls the isotope and the delivery network sets the pace for everyone else's trial timeline. Telix just bought the pace. ITM-11 still has to prove it deserves the milestone cheque.